BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 19885608)

  • 41. Epigenetic events of disease progression in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Meduri V; Nygren AO; Errami A; Schouten JP; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):668-77. PubMed ID: 16785414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epigenetic inactivation of RASSF1A in head and neck cancer.
    Dong SM; Sun DI; Benoit NE; Kuzmin I; Lerman MI; Sidransky D
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3635-40. PubMed ID: 14506151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
    Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
    PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation.
    Weiss D; Basel T; Sachse F; Braeuninger A; Rudack C
    Mol Carcinog; 2011 Sep; 50(9):680-8. PubMed ID: 21563216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.
    Meng RW; Li YC; Chen X; Huang YX; Shi H; Du DD; Niu X; Lu C; Lu MX
    Sci Rep; 2016 Feb; 6():20756. PubMed ID: 26857374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inactivation of the tumor suppressor genes causing the hereditary syndromes predisposing to head and neck cancer via promoter hypermethylation in sporadic head and neck cancers.
    Smith IM; Mithani SK; Mydlarz WK; Chang SS; Califano JA
    ORL J Otorhinolaryngol Relat Spec; 2010; 72(1):44-50. PubMed ID: 20332657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma.
    Carvalho AL; Chuang A; Jiang WW; Lee J; Begum S; Poeta L; Zhao M; Jerónimo C; Henrique R; Nayak CS; Park HL; Brait MR; Liu C; Zhou S; Koch W; Fazio VM; Ratovitski E; Trink B; Westra W; Sidransky D; Moon CS; Califano JA
    Cancer Res; 2006 Oct; 66(19):9401-7. PubMed ID: 17018594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis.
    Youssef EM; Lotan D; Issa JP; Wakasa K; Fan YH; Mao L; Hassan K; Feng L; Lee JJ; Lippman SM; Hong WK; Lotan R
    Clin Cancer Res; 2004 Mar; 10(5):1733-42. PubMed ID: 15014026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypermethylation of promoter region of LATS1--a CDK interacting protein in oral squamous cell carcinomas--a pilot study in India.
    Reddy VR; Annamalai T; Narayanan V; Ramanathan A
    Asian Pac J Cancer Prev; 2015; 16(4):1599-603. PubMed ID: 25743838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
    Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
    Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation.
    Dixit R; Kemp C; Kulich S; Seethala R; Chiosea S; Ling S; Ha PK; Duvvuri U
    Sci Rep; 2015 Nov; 5():16657. PubMed ID: 26563938
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma.
    Bennett KL; Karpenko M; Lin MT; Claus R; Arab K; Dyckhoff G; Plinkert P; Herpel E; Smiraglia D; Plass C
    Cancer Res; 2008 Jun; 68(12):4494-9. PubMed ID: 18559491
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.
    Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA
    Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LKB1 downregulation may be independent of promoter methylation or FOXO3 expression in head and neck cancer.
    Ekizoglu S; Dalay N; Karaman E; Akdeniz D; Ozaydin A; Buyru N
    Transl Res; 2013 Aug; 162(2):122-9. PubMed ID: 23810581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
    Murao K; Kubo Y; Ohtani N; Hara E; Arase S
    Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation.
    Coombes MM; Briggs KL; Bone JR; Clayman GL; El-Naggar AK; Dent SY
    Oncogene; 2003 Dec; 22(55):8902-11. PubMed ID: 14654786
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer.
    Demokan S; Chuang AY; Pattani KM; Sidransky D; Koch W; Califano JA
    Oncol Rep; 2014 Feb; 31(2):1014-20. PubMed ID: 24337411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
    Szaumkessel M; Wojciechowska S; Janiszewska J; Zemke N; Byzia E; Kiwerska K; Kostrzewska-Poczekaj M; Ustaszewski A; Jarmuz-Szymczak M; Grenman R; Wierzbicka M; Bartochowska A; Szyfter K; Giefing M
    Tumour Biol; 2017 Mar; 39(3):1010428317691427. PubMed ID: 28345455
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.
    Peyser ND; Freilino M; Wang L; Zeng Y; Li H; Johnson DE; Grandis JR
    Oncogene; 2016 Mar; 35(9):1163-9. PubMed ID: 25982282
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted.
    Poage GM; Christensen BC; Houseman EA; McClean MD; Wiencke JK; Posner MR; Clark JR; Nelson HH; Marsit CJ; Kelsey KT
    PLoS One; 2010 Mar; 5(3):e9651. PubMed ID: 20300172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.